# StrataPATH™ (Precision Indications for Approved Therapies)

> **NCT05097599** · PHASE2 · TERMINATED · sponsor: **Strata Oncology** · enrollment: 11 (actual)

## Conditions studied

- Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** lorlatinib
- **DRUG:** encorafenib + binimetinib
- **DRUG:** talazoparib
- **DRUG:** sacituzumab govitecan
- **DRUG:** axitinib
- **DRUG:** Fam-Trastuzumab Deruxtecan-Nxki
- **DRUG:** enfortumab vedotin

## Key facts

- **NCT ID:** NCT05097599
- **Lead sponsor:** Strata Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-29
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Business decision and enrollment difficulties
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097599, "StrataPATH™ (Precision Indications for Approved Therapies)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05097599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*